XGN Cash-Secured Put Strategy
XGN (Exagen Inc.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NASDAQ.
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.
XGN (Exagen Inc.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $83.8M, a beta of 1.81 versus the broader market, a 52-week range of 2.59-12.23, average daily share volume of 374K, a public-listing history dating back to 2019, approximately 209 full-time employees. These structural characteristics shape how XGN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.81 indicates XGN has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a cash-secured put on XGN?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current XGN snapshot
As of May 15, 2026, spot at $3.65, ATM IV 24.40%, IV rank 1.46%, expected move 7.00%. The cash-secured put on XGN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this cash-secured put structure on XGN specifically: XGN IV at 24.40% is on the cheap side of its 1-year range, which means a premium-selling XGN cash-secured put collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 7.00% (roughly $0.26 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated XGN expiries trade a higher absolute premium for lower per-day decay. Position sizing on XGN should anchor to the underlying notional of $3.65 per share and to the trader's directional view on XGN stock.
XGN cash-secured put setup
The XGN cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With XGN near $3.65, the first option leg uses a $3.47 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed XGN chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 XGN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $3.47 | N/A |
XGN cash-secured put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
XGN cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on XGN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use cash-secured put on XGN
Cash-secured puts on XGN earn premium while a trader waits to acquire XGN stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning XGN.
XGN thesis for this cash-secured put
The market-implied 1-standard-deviation range for XGN extends from approximately $3.39 on the downside to $3.91 on the upside. A XGN cash-secured put lets a trader earn premium while waiting to acquire XGN at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current XGN IV rank near 1.46% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on XGN at 24.40%. As a Healthcare name, XGN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to XGN-specific events.
XGN cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. XGN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move XGN alongside the broader basket even when XGN-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on XGN carry tail risk when realized volatility exceeds the implied move; review historical XGN earnings reactions and macro stress periods before sizing. Always rebuild the position from current XGN chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on XGN?
- A cash-secured put on XGN is the cash-secured put strategy applied to XGN (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With XGN stock trading near $3.65, the strikes shown on this page are snapped to the nearest listed XGN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are XGN cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the XGN cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 24.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a XGN cash-secured put?
- The breakeven for the XGN cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XGN market-implied 1-standard-deviation expected move is approximately 7.00%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on XGN?
- Cash-secured puts on XGN earn premium while a trader waits to acquire XGN stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning XGN.
- How does current XGN implied volatility affect this cash-secured put?
- XGN ATM IV is at 24.40% with IV rank near 1.46%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.